Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

NCT00110994 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Melanoma

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)
DRUG: Placebo
DRUG: Dacarbazine

Sponsor

Bayer

Collaborators

[object Object]